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Abstract 
 
Background & aims: Genome-wide association studies in adults have identified variants in 
HSD17B13 and MARC1 as protective against NAFLD. It is not known if they are similarly 
protective in children and, more generally, whether the peri-portal inflammation of pediatric 
NAFLD and lobular inflammation seen in adults share common genetic influences. Therefore, we 
aimed to: establish if these variants are associated with NAFLD in children, and to investigate the 
function of these variants in hepatic metabolism using metabolomics. 
Methods: 960 children (590 with NAFLD, 394 with liver histology) were genotyped for 
rs72613567T>TA in HSD17B13, rs2642438G>A in MARC1. Genotype-histology associations 
were tested using ordinal regression. Untargeted hepatic proteomics and plasma lipidomics were 
performed in a subset of samples. In silico tools were used to model the effect of rs2642438G>A 
(p.Ala165Thr) on MARC1. 
Results: rs72613567T>TA in HSD17B13 was associated with lower odds of NAFLD diagnosis 
(OR 0.7 (95%CI 0.6-0.9) and lower grade of portal inflammation (P<0.001) whilst rs2642438G>A 
in MARC1 was associated with lower grade of hepatic steatosis (P=0.02). Proteomics found 
reduced expression of HSD17B13 in carriers of the protective allele, whereas MARC1 levels were 
not affected by genotype. Both variants showed downregulation of hepatic fibrotic pathways, 
upregulation of retinol metabolism and perturbation of phospholipid species. Modelling suggests 
that p.Ala165Thr would disrupt the stability and metal-binding of MARC1. 
Conclusions: There are shared genetic mechanisms between pediatric and adult NAFLD, 
despite their differences in histology. MARC1 and HSD17B13 are involved in phospholipid 




Single nucleotide variant; steatohepatitis; metabolomics; liver biopsy. 
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Introduction 
Understanding genetic variants associated with human chronic disease phenotypes has yielded 
insights into multifactorial pathogenesis1. This is of particular importance in non-alcoholic fatty 
liver disease (NAFLD) as it is a common condition with potential to progress to end-stage liver 
disease and hepatocellular carcinoma2,3, yet has no licensed therapies4.  
 
Population level genome- and exome-wide association studies have identified several common 
variants implicated in the severity of NAFLD5. p.Ile148Met in patatin-like phospholipase 
domain-containing protein 3 (PNPLA3) is the variant most strongly associated with increased 
severity of NAFLD6,7 and has been well studied, leading to its identification as a lipid droplet-
binding protein that influences the recruitment of hydrolysing enzymes8,9. p.Glu167Lys in 
transmembrane 6 superfamily 2 (TM6SF2) is also well-established as a harmful variant that 
impairs hepatic lipid metabolism and increases risk of all stages of NAFLD10,11. 
 
More recently, strong human genetic evidence has identified two protective variants at genome-
wide significance: rs72613567T>TA in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13)12 
and p.Ala165Thr in mitochondrial amidoxime reducing component 1 (MARC1, rs2642438G>A)13. 
HSD17B13 has also been implicated in altered lipid metabolism, including recently in regulation 
of phospholipids14 and retinol15. However the function of MARC1 in hepatic lipid metabolism is 
largely unknown, though it clearly has drug detoxifying activity16,17 and has been recently 
implicated in phospholipid metabolism18. 
 
Histological validation of genetic variants is challenging due to the comparatively small numbers 
who undergo liver biopsy for NAFLD. This is even more so the case in pediatric NAFLD, therefore 
analyses studies are candidate gene studies in relatively small cohorts19,20. One genome-wide 
association study has been conducted in Hispanic boys with biopsy-proven NAFLD, which yielded 
several suggestive loci21. It is still unclear precisely how closely the genetics of adult and pediatric 
NAFLD overlap. 
 
Pediatric NAFLD is common (7.6% in the general population22) and shows a predominance of 
peri-portal inflammation and zone 1 steatosis, particularly in younger male patients23,24. Whilst 
both are positively associated with insulin resistance and other features of the metabolic 
syndrome25, it is not clear whether pediatric peri-portal inflammation in NAFLD is simply a 
childhood manifestation of ‘adult’ NASH (with lobular inflammation and ballooning) or a different 
pathophysiological entity. 
 
Therefore, we sought to address whether the protective variants in HSD17B13 and MARC1 
identified at a population-level in adults can be replicated in children with NAFLD, also providing 
histological validation of p.Ala165Thr in MARC1. In this study we used liver tissue proteomics and 
plasma lipidomics to gain insight into the impact of these variants on hepatic metabolism in 
children with NAFLD.  
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Methods 
Participants 
Two groups of participants were included in this cross-sectional study: cases (children with 
NAFLD) and controls (without NAFLD). A subset of children with NAFLD had undergone liver 
biopsy for clinical indications. All participants (or their parents) gave written informed consent and 
were recruited between 2014-2019. 
Participants were recruited from six sites. Children with NAFLD were recruited from hepatology & 
gastroenterology clinics in Cambridge & Birmingham (UK) as part of the European Paediatric 
NAFLD Registry (EU-PNAFLD, Clintrials.gov NCT:04190849)26, which was approved by the East 
Midlands - Nottingham 2 Research Ethics Committee (17/EM/0084). 
Obese controls and NAFLD cases were recruited from pediatric obesity clinics at Maastricht 
University Medical Centre (under ethical approval METC 13-4-130) and Amsterdam University 
Medical Centre (under ethical approval MEC 2017_306 and MEC 07/141). Obese controls and 
NAFLD cases were recruited from Bambino Gesu hospital (under ethical approval for EU-
PNAFLD and local Ethics Review Board, protocol number 1774_OPBG_2019). Children were 
referred to these clinics due to obesity and were then subsequently investigated for co-
morbidities, including NAFLD. Children identified to have NAFLD were recruited as cases and 
those with obesity but no evidence of liver disease (as described below) were included in this 
study as obese controls. 
In addition, NAFLD cases were recruited from the Berlin Cohort27 at the pediatric obesity 
outpatient clinic and pediatric gastroenterology outpatient clinic of Charité (under ethical approval 
of the local institutional review board EA2/049/14).  
Recruitment of controls from the same clinics (and referral populations) as cases aimed to reduce 
the bias of case-control comparisons. Recruitment from multiple different hospitals aimed to 
reduce bias associated with a sample from a single hospital population. As an exploratory 
analysis, we utilised data from the maximum number of available participants therefore no formal 
sample size calculation was performed.  
 
Inclusion and exclusion criteria 
All participants were 5-18 years old at the time of inclusion. 
 
Cases (n=590): All cases were identified with abnormal biochemistry (alanine aminotransferase 
(ALT) >44U/l for girls or >50 U/l for boys and/or aspartate aminotransferase (AST) >50 U/l28) 
and/or radiological evidence of steatosis (ultrasound, magnetic resonance imaging, or controlled 
attenuation parameter ≥240). Imaging was available for 571 patients (97%). Liver biopsy with 
histological characterization of NAFLD was available for 394 (67%) patients.  
 
Controls (n=412): NAFLD was excluded by absence of hepatic steatosis upon radiologic 
examination (ultrasound, magnetic resonance imaging, or controlled attenuation parameter 
<240), or where not available (n=177, 43%) with normal aminotransferases. 
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Exclusion criteria were: age <5 or >18 years, any other liver disease (assessment for secondary 
causes including: alpha-1-antitrypsin deficiency, celiac disease, autoimmune hepatitis, viral 
hepatitis A, B and C, active cytomegalovirus or Epstein-Barr virus infection, thyroid disorders, and 
Wilson’s disease), severe underlying chronic disease (e.g., cardiopulmonary or autoimmune 
disease), alcohol consumption >20 g of alcohol per day, and pregnancy. 
 
Children with incomplete data, inadequate genotyping quality or unclear genotyping call were also 
excluded. Thirty-six patients initially recruited were excluded, 32 were under 5 or over 18 years 
old, 2 with unclear diagnosis, and 4 without adequate data. 
 
Clinical and laboratory investigations 
In all cases and obese controls included in the study, anthropometric measures (height, weight) 
were taken, laboratory analysis including a hepatic panel and complete blood count was 
performed, and fasted state metabolic parameters were assessed by using standardized 
procedures. The homeostatic model assessment of insulin resistance (HOMA-IR) was derived 
using fasting insulin (µU/L) x fasting glucose (nmol/L) / 22.5. Obesity was defined as body mass 
index (BMI) z-score >2. 
 
Genotyping 
DNA was extracted from whole blood (using Qiagen DNeasy kit #69504). Participants were 
genotyped by quantitative polymerase chain reaction using TaqMan assays (ThermoFisher 
#4351379): rs738409C>G in PNPLA3, rs58542926C>T in transmembrane 6 superfamily 2 
(TM6SF2), rs2642438G>A in MARC1, and rs72613567T>TA in HSD17B13 (using the custom 
sequence from Pirola et al.29). These variants were selected due to their evidence as genome-
wide risk factors for NAFLD and cirrhosis in adults6,7,10,12,13,30,31. Data on variants in HSD17B13 
and MARC1 were available for 960 participants whilst data on PNPLA3 variants were available 
for 490 participants and data on TM6SF2 variants were available for 489 participants. 
All variants were within Hardy-Weinberg equilibrium in the control groups using Chi-squared test: 
rs58542926C>T in TM6SF2, P = 0.08; rs2642438G>A in MARC1, P = 0.21; and rs72613567T>TA 




Liver biopsies were evaluated and scored by experienced pathologists of the respective centers. 
Staging and grading was performed according to the histological scoring system for non-alcoholic 
fatty liver disease by the Nonalcoholic Steatohepatitis Clinical Research Network (NASH-CRN)32. 
Briefly, grading included the scoring of steatosis (0= <5%; 1= 5-33%; 2= 34-66%; 3= ≥67%), 
lobular inflammation (0= 0/200x field; 1= <2 foci/200x field; 2= 2-4 foci/200x field; 3= >4 foci/ 200x 
field), and hepatocellular ballooning (0= none; 1= few; 2= many/prominent). Portal inflammation 
was evaluated according to Brunt et al.33 (0= none; 1= mild; 2 = moderate to severe). Staging of 
fibrosis was performed using NASH-CRN criteria (0= no fibrosis; 1= zone 3 perisinusoidal only or 
portal/periportal without bridging only; 2= zone 3 perisinusoidal + portal/periportal; 3= bridging 
fibrosis; 4= cirrhosis).  
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Hepatic proteomic analysis 
Hepatic tissue proteomics was performed in a subset of 70 patients, as previously described27. 
Liver biopsy specimens were extracted under denaturing conditions and digested by trypsin for 
subsequent analysis by mass spectrometry34. The software tools MaxQuant35 and gene set 
enrichment analysis (GSEA)36 were used for peptide identification and pathway analyses, 
respectively (see Supplementary Methods for details). 
 
In silico analysis of MARC1 p.Ala165Thr 
Our hepatic proteomics data suggested that this MARC1 variant did not alter expression of 
MARC1 protein, unlike for the studied HSD17B13 variant. Therefore, to further provide some 
insight into the impact of rs2642438G>A (p.Ala165Thr) in MARC1 we used a range of 
bioinformatics tools to perform an in silico analysis of the variant. UniProt37 was searched for 
isoforms of MARC1 in other species and sequences aligned. Four tools were chosen to be used 
for prediction of the impact of the missense variant based on recommendations of accuracy from 
the range of tools available38,39: SNPs&GO40, PANTHER41, Align-GVGD42, and MutPred243. For a 
structural analysis, we used the available crystal structure of MARC144 and three tools for 
calculating the effect of p.Ala165Thr on overall protein stability: I-Mutant3.045, DUET46, and 
CUPSAT47. Data on in silico saturation mutagenesis of MARC1 were available from EVmutation. 
An annotated protein model was generated using UCSF Chimera48. 
 
Plasma lipidomics analysis 
Plasma lipidomics was performed in a subset of 129 children with NAFLD who had undergone 
liver biopsy. The methods have been described in detail elsewhere49, but in brief, lipids, 
triglycerides and sterols were extracted together from fasting plasma using a high throughput 
technique followed by direct infusion mass spectrometry (DI-MS)50. 
 
Data acquisition--Samples were infused into an Exactive Orbitrap (Thermo, Hemel Hampstead, 
UK), using a Triversa Nanomate (Advion, Ithaca, NY, USA). Positive ionisation mode was 
achieved at a 1·2 kV. The Exactive started acquiring data 20 s after sample aspiration began. 
The Exactive acquired data with a scan rate of 1 Hz (resulting in a mass resolution of 65,000 full 
width at half-maximum (fwhm) at 400 m/z). After 72 s of acquisition in positive mode the Nanomate 
and the Exactive switched over to negative mode, decreasing the voltage to −1·5 kV. The spray 
was maintained for another 66 s, after which Collision-Induced Dissociation commenced, with a 
mass window of 50–1000 Da, and was stopped after another 66 s. The sample plate was kept at 
10 °C throughout the data acquisition. 
 
Data processing--Raw high-resolution mass-spectrometry data were converted to mzXML files 
and then processed using XCMS (www.bioconductor.org) and Peakpicker v 2.0 (an in-house R 
script51). Lists of known species (by m/z) were used for both positive ion and negative ion mode 
(~8·5k species). Identification of species was compared against validated lists of species used by 
this group51–55. Variables whose mass deviated by more than 9 ppm from the expected value, had 
a signal-to-noise ratio of <3 and had signals for fewer than 50% of samples were discarded. 
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Signals were then divided by the sum of signals for that sample and expressed per mille (‰). 




Testing for normal distribution was performed for all variables using the Shapiro-Wilk method. 
Frequencies and percentages are presented for clinical (categorial) and histological (ordinal)  
characteristics.  Medians and quartiles of continuous anthropometric and laboratory parameters 
were calculated for the total study population as well as for subgroups (stratification for the 
presence of NAFLD, variant genotype within cases, patients with proteomic or lipidomic profiles). 
To evaluate differences in distribution between cases and controls as well as within genotypes of 
variants we used  Kruskal-Wallis test for continuous nonparametric values (age, BMI-z score). 
Chi-squared tests were applied to categorical and ordinal variables (gender and presence of 
obesity). For all continuous laboratory values, linear regression models with correction for age 
and gender were used.    
Hardy-Weinberg equilibrium was tested using a chi-squared test with one degree of freedom for 
all genetic variants. Case-control studies between the different genotypes were analyzed using 
chi-squared tests and logistic regression models for distinct genetic modes of inheritance:  no 
particular genetic model (genotypes), additive (trend), dominant, recessive or multiplicative 
(alleles). Additive (or linear mixed) genetic models were used in the identification of these variants 
as significant risk loci12,13 and therefore we have primarily used the additive model in all analyses. 
Effects of variants were calculated using Wald tests, odds ratios (OR) and 95% confidence 
intervals (95% CIs). False discovery rate-adjusted Q-values were calculated using the Benjamini-
Hochberg procedure to adjust for multiple testing. Associations between genotypes and 
histological features were tested using univariate ordinal regression or multivariate ordinal 
regression models with correction for age, sex, BMI z-score and HOMA-IR. Dichotomous 
histological associations were tested by binary logistic regression with correction for age and sex. 
OR and 95% CIs were calculated. Genotype was coded by number of ‘protective’ alleles: 
HSD17B13 rs72613567 T/T=0, T/TA=1, TA/TA=2; and MARC1 rs2642438 G/G=0, G/A=1, A/A=2. 
Proteomic studies: see Supplementary Methods.   
Lipidomic studies: relative abundances for each lipid were logarithmically transformed and 
standardised (to mean = 0, standard deviation = 1). Missing values were ignored and no 
imputation was used. Linear regression analyses adjusted for sex and age were run to test for 
associations between lipid species and genotype. The beta regression coefficients were then 
plotted against length of carbon chain and number of double-bonds. Due to high correlation 
between lipid species, the critical p-value for significance was defined by 0.05/√n, where n is the 
number of identified species from each analysis method. 
Statistical analysis was performed in SPSS (IBM Corp. Released 2017. IBM SPSS Statistics for 
Windows, Version 25.0. Armonk, NY: IBM Corp). Further regression analysis was performed in 
Stata v16.1 (StataCorp) and random forest analysis was performed using R 3.6.156, in addition, 
graphs were produced in GraphPad v8.0 for Mac, GraphPad Software, La Jolla California, USA.  
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Results 
 
Characteristics of the study population 
One thousand two children (590 with NAFLD and 412 controls) were included in the study. 
Children with NAFLD were older, more likely to be male, more insulin resistant and dyslipidemic 
despite being less obese (Table 1). They exhibited higher liver transaminases, with median ALT 
being elevated more than 2 times as compared to the control group.   
 
 
Association between variants in MARC1, HSD17B13, TM6SF2, 
PNPLA3 and NAFLD 
First, we sought to determine whether these variants were associated with diagnosis of NAFLD 
in children (Figure 1). rs738409C>G in PNPLA3 was positively associated with diagnosis of 
NAFLD (odds ratio (OR) 1.79 (95% CI 1.26-2.53). rs72613567T>TA in HSD17B13 was protective 
against diagnosis of NAFLD (OR 0.70 (95% CI 0.56-0.87)) though no association with diagnosis 
of NAFLD was observed with rs2642438G>A in MARC1 or rs58542926C>T in TM6SF2 




Figure 1. Odds ratios for the presence of NAFLD using an additive genetic model. Data from 590 
children with NAFLD (cases) and 370 controls. P-values were calculated using logistic regression 
with correction for age and sex.  ‘PNPLA3’ refers to rs738409C>G, ‘MARC1’ refers to 
rs2642438G>A, and ‘HSD17B13’ refers to rs72613567T>TA and ‘TM6SF2‘ refers to 
rs58542926C>T. 
 
In children with NAFLD, rs72613567T>TA in HSD17B13  and rs2642438G>A in MARC1 were not 
associated with any anthropometric or biochemical traits (Supplementary Tables 2 & 3). 
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Effect of single nucleotide variants on histological severity of 
NAFLD 
 
Of those with NAFLD, 394 (67%) had undergone liver biopsy (Table 2 & Supplementary Table 4). 
Participants displayed the whole spectrum of NAFLD from simple steatosis to NASH-associated 
cirrhosis.  70% had evidence of peri-portal inflammation and 13% had advanced fibrosis (stage 
3-4). 
 
Consistent with its well-established harmful effect on NAFLD in adults, rs738409C>G in PNPLA3 
was associated with a higher grade of steatosis (P = 3.2x10-5), lobular inflammation (P = 0.02, 
and fibrosis stage (P = 0.02) on multivariable ordinal regression adjusted for age, sex, BMI, and 
HOMA-IR (Figure 2 & Supplementary Table 5). 
 
Whereas, variants in HSD17B13 and in MARC1 were associated with less advanced histological 
features (Figure 2 & Supplementary Table 5). rs72613567T>TA in HSD17B13 was strongly 
associated with lower grade of portal inflammation (P = 1.5x10-4) and rs2642438G>A in MARC1 
was associated with lower grade of steatosis (P = 0.02). Both protective variants showed a trend 
towards a lower fibrosis stage but no significant association on ordinal regression analysis. 
Similar results were observed using a dichotomous analysis: PNPLA3 increased odds for the 
development of both moderate fibrosis (OR 1.33 (95% CI 1.00 - 1.78)) and advanced fibrosis (OR 
1.96 (95% CI 1.29 - 3.00)), while HSD17B13 and MARC1 were associated with lower odds for 
moderate fibrosis (OR 0.66 (95% CI 0.45 - 0.99) or advanced fibrosis (OR 0.53 (95%CI 0.30 - 
0.94)) respectively (Supplementary Figure 1 & Supplementary Table 6).   
 
There was no association of rs58542926C>T in TM6SF2 with any histological trait 
(Supplementary Tables 5 & 6). 
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Figure 2. Effect of SNV on histological severity of NAFLD in children. Data from 394 children 
genotyped for rs738409C>G (PNPLA3), rs72613567T>TA (HSD17B13) and rs2642438G>A 
(MARC1). Multivariate ordinal regression analysis with correction for age, sex, BMI z-score and 
HOMA-IR was performed for the association of the respective genotypes with (A) fibrosis stage 




Liver proteomics implicates variants in HSD17B13 and MARC1 in 
fibrosis and lipid metabolism 
In order to understand the effect of these variants on liver function, we performed proteomics on 
liver biopsy samples from 70 children with NAFLD, who were representative of the overall NAFLD 
group (Supplementary Table 7). rs72613567T>TA was associated with lower abundance of 
HSD17B13 liver protein (Figure 3A&B & Supplementary Table 8). Whereas hepatic levels of 
MARC1 protein did not appear to be affected by rs2642438G>A genotype (Figure 3C & 
Supplementary Table 8). 
Gene set enrichment analysis (GSEA) for rs72613567T>TA in HSD17B13 genotype implicated 
changes in multiple gene sets, including a strong upregulation of ribosomal activity (e.g. 
KEGG_RIBOSOME, normalized enrichment score (NES) = 3.0; Q = 0)  and nonsense-mediated 
decay (e.g. REACTOME_NONSENSE_MEDIATED_DECAY, NES = 2.74; Q = 0), consistent with 
degradation of mutant HSD17B13 (Supplementary Table 9). When the enriched gene sets were 
mapped for similarity (Figure 3D) several trends could be observed: there was a strong signature 
of downregulation of pathways associated with immune response (e.g. 
HALLMARK_INTERFERON_GAMMA_RESPONSE, NES = -2.4, Q = 0). Multiple metabolic 
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pathways appeared to be perturbed including upregulation of fatty acid processing (e.g. 
KEGG_FATTY_ACID_METABOLISM, NES = 2.82; Q = 0) . There was also downregulation of 
pathways and proteins associated with extracellular matrix formation (e.g. 
GO_COLLAGEN_CONTAINING_EXTRACELLULAR_MATRIX, NES = -1.9; Q = 0.047). 
 
GSEA for rs2642438G>A in MARC1 similarly found a strong signature for downregulation of 
extracellular matrix and collagen-related pathways (e.g. GO_COLLAGEN_TRIMER, NES: -2.46, 
Q = 0.010 and GO_EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT, NES = -2.35; 
Q = 0.018) as well as gene sets related to the innate immune response (Figure 3E & 
Supplementary Table 9). There was a strong enrichment in gene sets associated with 
mitochondrial metabolism, drug detoxification, sphingolipid metabolism, and redox reactions (e.g. 
GO_SPHINGOLIPID_METABOLIC_PROCESS, NES = 2.15, Q = 0.05  and 
GO_OXIDOREDUCTASE_ACTIVITY, NES = 1.9, Q = 0.16). 
 
GSEA for both protective variants demonstrated an upregulation of retinol metabolism (NES = 
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Figure 3. Liver proteomics in children with NAFLD, stratified by  rs72613567T>TA in HSD17B13 
& rs2642438G>A in MARC1 variants. (A) A volcano plot of log2 abundance ratios against the -
log10 (p-value) of the proteome for the HSD17B13 TA/TA vs. T/T genotype. (B) Absolute 
abundance levels (LFQ intensity) stratified by genotype for HSD17B13 liver protein and (C) 
MARC1 liver protein. Reported P values were calculated using Kruskal-Wallis test. (D) 
Enrichment map of up- (red) or downregulated (blue) pathways for HSD17B13 genotype as 
discovered by gene set enrichment analysis using an additive genetic model. (E) Enrichment map 
of up- (red) or downregulated (blue) pathways for MARC1 genotype as discovered by gene set 
enrichment analysis using an additive genetic model.  
 
 
In silico analysis of MARC1 p.Ala165Thr indicates loss of stability 
rs72613567T>TA in HSD17B13 falls at a splice-site and our proteomics data suggests this results 
in reduced expression through nonsense mediated decay. However, the effect of rs2642438G>A 
(coding for p.Ala165Thr) on MARC1 is less clear, as our proteomics results did not show any 
change in expression of MARC1 with genotype. 
MARC1 position 165 lies within the cytoplasm (with positions 2-20 within the mitochondrial matrix) 
and is part of the MOSC (MOCO sulfurase C-terminal) domain. The crystalline structure of 
MARC1 has been resolved to 1.78Å and shows that alanine-165 forms part of an alpha-helix on 
the external surface of the enzyme (Figure 4A&B). Alanine-165 is highly conserved across 
mammals (Figure 4C), though the Zebrafish isoform of MARC1 has a different structure in this 
region. Using in silico saturation mutagenesis, we observed that Alanine-165 is considered to 
have a substantial beneficial effect on the protein, compared to other predicted missense variants 
in MARC1 (Figure 4D). Whilst position 165 is not within any of the predicted active sites of 
MARC1, two prediction tools classified the p.Ala165Thr variant as disease causing, suggesting 
that it would cause loss of the alpha-helix and alter the metal binding ability of MARC1 
(Supplementary Table 10). Consistent with this, the p.Ala165Thr variant is also predicted to affect 
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Figure 4. In silico prediction of the effects of p.Ala165Thr on MARC1. Alanine-165 (green) forms 
part of an alpha helix (A) and forms part of the external surface of MARC1 (B). This position is 
highly conserved in mammals using alignment of protein isoforms (C). Saturation mutagenesis 
results from EVmutation predicts an increase in protein function (red) when substituting alanine 




Plasma lipidomics shows variants in HSD17B13 and MARC1 
perturb phospholipid metabolism 
Given that proteomics data implicates these protective variants in (glycerophospho)-lipid 
metabolism, we performed untargeted plasma lipidomics in 129 children with biopsy-defined 
NAFLD and who were representative of the overall NAFLD group (Supplementary Table 11). We 
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tested for associations between variant genotypes and lipid species using linear regression, 
adjusted for age and sex. 
rs72613567T>TA in HSD17B13 was associated with changes in phosphatidylcholines (PC) and 
fatty acids (FA) derived from phospholipids (Figure 5A-C). This variant showed a trend towards 
positive associations with unsaturated FA and negative associations with polyunsaturated FA 
(Figure 5C). The opposite trend was observed with phosphatidylethanolamines (Supplementary 
Figure 2). rs2642438G>A in MARC1 was negatively associated with PC (Figure 5D), again 
unaffected by chain length (Figure 5E & Supplementary Figure 3), and with phosphatidylinositols 
(PI, Figure 5F). 
The harmful variant rs738409C>G in PNPLA3 was also associated with changes in PC, though 
the direction was influenced by the number of double bonds and carbon chain length 
(Supplementary Figure 4). 
These associations did not appear to be reflective of changes in fibrosis stage, steatosis, or 
inflammatory activity (Supplementary Figure 5). Fibrosis stage was negatively associated with PC 
chain length and number of double bonds, whilst NAFLD Activity Score was negatively associated 
with triglyceride chain length. 
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Figure 5. Plasma lipid species associated with rs72613567T>TA in HSD17B13 and 
rs2642438G>A in MARC1. Volcano plots (A & D) demonstrating the association (as beta-
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regression coefficient) between lipid species and variants, where beta-regression coefficient was 
calculated by linear regression between genotype (coding T/T=0, T/TA=1, TA/TA=2) and 
logarithmically-transformed lipid abundance, adjusted for age and sex. rs72613567T>TA in 
HSD17B13 was negatively associated with a higher number of double bonds in fatty acids (FA, 
B). Whilst rs2642438G>A in MARC1 was negatively associated with a higher number of double 
bonds in phosphatidylinositols (PI). Simple linear regression with 95% confidence intervals are 
shown in red. Data from 129 children with biopsy-confirmed NAFLD. CE, cholesterol esters; Cer, 
ceramides; Chol, cholesterol; DG, diglycerides; LPC, lyso-phosphatidylcholines; PA, phosphatidic 
acids; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PG, phosphatidylglycerols; PS, 
phosphatidylserines; SM, sphingomyelin; TG, triglycerides. 
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Discussion 
In this study we have provided histological validation of protective MARC1 and HSD17B13 
variants in children with NAFLD. Both variants were associated with perturbed phospholipid 
metabolism and downregulation of fibrotic pathways. Unlike rs72613567T>TA in HSD17B13, 
hepatic expression of MARC1 is not affected by p.Ala165Thr, suggesting a mechanism of reduced 
function. 
 
Both rs72613567T>TA in HSD17B1312 and rs2642438G>A in MARC113 were originally identified 
as GWAS-significant risk-reducing loci for liver disease in adults, most recently as risk-reducing 
variants for all-cause cirrhosis (as well as NAFLD cirrhosis). HSD17B13 has subsequently been 
validated in multiple cohorts of adults6,14,15,29,57–59 though the histological features associated with 
this variant in MARC1 has not been described in children until now18. We therefore selected these 
two variants to study in children, in addition to the well-established risk-increasing locus 
rs738409C>G in PNPLA3 and rs58542926C>T in TM6SF2. 
 
The splice variant rs72613567T>TA in HSD17B13 has been consistently associated with lower 
grade of lobular inflammation, NASH, and stage of fibrosis in adults12, though without any 
difference in severity of histological steatosis14,29. In children we observed a strong negative 
association with grade of peri-portal inflammation with no effect on lobular inflammation. Pediatric 
NASH is often characterized by a ‘zone 1’ predominant distribution of steatosis and inflammation, 
particularly in younger children23. Whilst it has been speculated that the peri-portal inflammation 
of pediatric NASH ‘transitions’ to lobular inflammation (and ballooning) of adult NASH, it is 
challenging to prove. Here, we have observed a genetic variant that has a specific association 
with peri-portal inflammation in children and with lobular inflammation in adults. We believe this 
provides further evidence to support the notion that pediatric NASH shares similar genetics to 
adult NASH, despite having a different histological patterns. 
 
Several groups have previously demonstrated that the splice variant rs72613567T>TA in 
HSD17B13 is associated with reduced expression of the enzyme12,14,29, which we have replicated 
using proteomics. Our pathway analysis also suggested an increase in nonsense-mediated 
decay, similar to the expression profiling data from Sookoian et al29. The function of this enzyme 
is not exactly clear but has been recently implicated in phospholipid metabolism14. Our proteomic 
and lipidomic data is generally concordant with reduced expression of HSD17B13 causing 
perturbation of glycerophospholipid metabolism. Though we did not observe precisely the same 
pattern of altered lipid species as reported by Luukkonen et al.14, we used plasma, rather than 
hepatic tissue, for lipid profiling. 
 
The MARC1 variant discovered by Emdin et al. was associated with lower odds of all-cause 
cirrhosis, diagnosis of fatty liver, and lower liver fat on CT13. Consistent with this, in children with 
NAFLD we found a negative association with severity of steatosis, however we did not replicate 
the finding of lower odds of NAFLD diagnosis. Whilst there was only a negative trend in fibrosis 
stage our proteomics data gave a signal of downregulation of fibrotic pathways. One explanation 
for these findings is that this variant primarily reduces hepatic fat and reduced fibrosis (i.e. 
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cirrhosis in adults) is a secondary effect. Data from other variants associated with liver fat does 
suggest, via a Mendelian randomization method, that degree of steatosis is causally associated 
with fibrosis stage60. However from our, and others’ observations, the lack of correlation between 
steatosis and fibrosis stage with rs72613567T>TA in HSD17B13 suggests that the two 
histological features can be dissociated. Further mechanistic investigation will be needed to 
understand the link between these variants, steatosis, and fibrosis. 
 
The precise role of MARC1 in hepatic metabolism is unknown. We found this enzyme to be 
expressed at similar levels across rs2642438G>A genotypes, even though the variant 
(p.Ala165Thr) would be predicted to have a destabilizing effect. MARC1 is a molybdenum-
dependent enzyme that reduces N-oxygenated molecules17,44. We found that alanine 165 is highly 
conserved and threonine-165 may disrupt the alpha-helix and its ability to bind molybdenum. This 
does appear to affect lipid metabolism as it was associated with reduced abundance of specific 
plasma phospholipids. Though precisely how this achieved will require further characterization. 
 
Our proteomics showed a consistent trend of increased retinol metabolism associated with 
HSD17B13 and MARC1 variants, whilst it was reduced with the PNPLA3 variant, as reported 
previously27. Whilst it is possible that a specific common mechanism underlies this, it may also be 
a secondary observation. Mechanistic work does implicate PNPLA361 and HSD17B13 in retinol 
metabolism15 but it is not known for MARC1. These results could also be accounted for by 
activation of hepatic stellate cells62 in the context of more advanced NAFLD, with an 
accompanying down-regulation of their retinol metabolism. More generally it is unclear whether 
disordered retinol metabolism is causal in severity of NAFLD. 
 
The strengths of this study include a comparatively large number of histologically characterised 
children and use of unbiased lipidomics and proteomics work to give insights into variant function. 
Also, replication of well-established associations with rs738409C>G in PNPLA3 provides further 
confidence in our findings. Studying paediatric subjects with NAFLD reduces the risk of interaction 
with factors attributable to adult multimorbidity or substance toxicity.  
 
In this study we were unable to account for genetic ancestry in analyses due to use of genotyping 
individual variants. Also, we did not observe an association between rs58542926C>T in TM6SF2 
and NAFLD severity, which may have been due to relatively few T-allele carriers. In addition, we 
may have had reduced power for case-control analyses by use of ultrasound and 
aminotransferases (rather than more sensitive techniques) for exclusion of steatosis.  Therefore, 
some children with mild steatosis may have been assigned to the control group. Finally, 
comparatively few children with advanced NAFLD may have meant reduced power to identify 




rs72613567T>TA in HSD17B13 and rs2642438G>A in MARC1 are protective against severity of 
pediatric NAFLD, suggesting shared genetic effects between adults and children. Proteomic and 
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lipidomic data implicate the effect of these two variants with perturbation of phospholipid 
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 Table 1. 
 Clinical and Laboratory Characteristics. 
Variable Control (N = 412) NAFLD (N = 590)         P value       Q value 
Age (years) 12.3 (10.0 – 14.7)  13.0 (11.0 – 15.4)  7.6 x 10-5 1.2 x 10-4 
Male sex, n (%) 181 (43.9) 386 (66.6)  1.1 x 10-8 2.9 x 10-8 
BMI z-score 3.1 (2.6 – 3.5) 2.4 (1.8 – 3.0)  1.6 x 10-25  8.5 x 10-25 
Obesity, n (%) 325 (78.9) 387 (66.5) 2.2 x 10-5 3.9 x 10-5 
ALT (U/l) 21 (17 – 28) 47 (31 – 78)   1.4 x 10-37  2.2 x 10-36 
AST (U/l) 25 (20 – 30) 38 (28 – 54)   2.0 x 10-29  1.6 x 10-28 
GGT (U/l) 16 (13 – 20) 23 (16 – 36)   1.5 x 10-14    6.0 x 10-14 
Cholesterol (mg/dl) 158 (139 – 178) 160 (139 – 185)     0.531   0.571 
LDL (mg/dl) 93 (75 – 112) 97 (81 – 112)     0.488   0.571 
HDL (mg/dl) 46 (39 – 54) 43 (38 – 50) 3.0 x 10-7 6.9 x 10-7 
Triglycerides (mg/dl) 81 (57 – 108) 98 (71 – 141) 4.0 x 10-6 8.0 x 10-6 
HOMA 2.6 (1.7 – 4.0) 3.7 (2.5 – 5.6)  2.8 x 10-10  9.0 x 10-10 
HSD17B13 genotype, n (%)     
TT / TTA / TATA 206 (55.7)/143 (38.6)/21 (5.7) 394 (66.8)/168 (28.5)/28 (4.7)     0.002 0.003 
MARC1 genotype, n (%)     
GG / GA / AA 199 (53.8)/151 ( 40.8)/20 (5.4) 324 (54.9)/227 (38.5)/39 (6.6)     0.889 0.889 
PNPLA3 genotype, n (%)     
CC / CG / GG 48 (49.5)/42 (43.3)/7 (7.2) 139 (35.4)/172 (43.8)/82 (20.9)     0.001 0.001 
TMF6SF2 genotype, n (%)     
CC / CT / TT 84 (87.5)/11 (11.5)/1 (1.0) 337 (85.8)/52 (13.2)/4 (1.0)    0.535 0.571 
 
Table 1.  Data represent frequencies (%) or median (interquartile range) as appropriate. For clinical characteristics, P-values were calculated using 
Mann-Whitney U test for continuous traits and Chi-square test for categorical traits. For plasma markers, P-values were calculated using linear regression 
with correction for age, sex. For genotypes, P-values were calculated using binary logistic regression with correction for age and sex (Wald test). FDR 
correction (Q value) for multiple comparisons was calculated using the Benjamini and Hochberg method. BMI, body mass index; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase; LDL, low density lipoprotein; HDL, high density lipoprotein; 
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Table 2. 
Histologic Findings. 
Grade / Stage Steatosis  
(N= 394) 
Portal Inflammation 
(N = 386)  
Lobular Inflammation 
(N = 394) 
Ballooning  
(N = 388) 
 Fibrosis 
(N = 393)  
0      - 117 (30.3)   77 (19.5) 121 (31.2)   90 (22.9) 
1   90 (22.8) 226 (58.5) 202 (51.3) 161 (41.5) 152 (38.7) 
2 187 (47.5)   43 (11.1) 115 (29.2) 106 (27.3)   99 (25.2) 
3 117 (29.7)     -     -     -   50 (12.7) 
4     -     -     -     -     2 (00.5) 
 
Table 2. Data represent frequencies (%) of histologic findings in the biopsied study population (N = 394).  
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